- Home
- EYPT vs ERAS Comparison
EYPT vs ERAS Comparison
Compare EYPT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- ERAS
- Stock Information
- Founded
- EYPT 1987
- ERAS 2018
- Country
- EYPT United States
- ERAS United States
- Employees
- EYPT N/A
- ERAS N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- ERAS Health Care
- Exchange
- EYPT Nasdaq
- ERAS Nasdaq
- Market Cap
- EYPT 484.4M
- ERAS 348.4M
- IPO Year
- EYPT 2005
- ERAS 2021
- Fundamental
- Price
- EYPT $8.25
- ERAS $1.57
- Analyst Decision
- EYPT Strong Buy
- ERAS Strong Buy
- Analyst Count
- EYPT 8
- ERAS 6
- Target Price
- EYPT $24.29
- ERAS $4.83
- AVG Volume (30 Days)
- EYPT 895.1K
- ERAS 1.6M
- Earning Date
- EYPT 05-07-2025
- ERAS 05-13-2025
- Dividend Yield
- EYPT N/A
- ERAS N/A
- EPS Growth
- EYPT N/A
- ERAS N/A
- EPS
- EYPT N/A
- ERAS N/A
- Revenue
- EYPT $56,042,000.00
- ERAS N/A
- Revenue This Year
- EYPT N/A
- ERAS N/A
- Revenue Next Year
- EYPT N/A
- ERAS N/A
- P/E Ratio
- EYPT N/A
- ERAS N/A
- Revenue Growth
- EYPT 12.04
- ERAS N/A
- 52 Week Low
- EYPT $3.91
- ERAS $1.01
- 52 Week High
- EYPT $13.99
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- EYPT 72.87
- ERAS 62.94
- Support Level
- EYPT $5.46
- ERAS $1.26
- Resistance Level
- EYPT $8.36
- ERAS $1.47
- Average True Range (ATR)
- EYPT 0.57
- ERAS 0.14
- MACD
- EYPT 0.24
- ERAS 0.04
- Stochastic Oscillator
- EYPT 96.21
- ERAS 79.69
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.